GLP-1 Titration Schedule: Semaglutide vs. Tirzepatide Compared
Both semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) require strict weekly titration to manage GI side effects. Here's the manufacturer schedule for each, common deviations, and what to track week-over-week.
Semaglutide titration
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg/week |
| 5–8 | 0.5 mg/week |
| 9–12 | 1.0 mg/week |
| 13–16 | 1.7 mg/week |
| 17+ | 2.4 mg/week (maintenance) |
Tirzepatide titration
| Weeks | Dose |
|---|---|
| 1–4 | 2.5 mg/week |
| 5–8 | 5 mg/week |
| 9–12 | 7.5 mg/week |
| 13–16 | 10 mg/week |
| 17–20 | 12.5 mg/week |
| 21+ | 15 mg/week (max) |
Common deviations
Many users (with or without clinician input) deviate from these schedules: holding longer at a tolerated dose, advancing slower if side effects persist, or stepping down if a higher dose causes problems. Peptra lets you advance manually rather than auto-progressing.
What to track on GLP-1s
- Weight, weekly at the same time and conditions
- Side effects: nausea, fatigue, constipation, sulfur burps — score 0–3 for severity
- Appetite: subjective scale, useful for knowing when to titrate up vs. hold
- Hydration and protein intake: muscle preservation matters at higher doses
The titration ladder is rigid; what you eat, drink, and feel during it varies enormously. Peptra puts both in the same place.